Effects of aerobic training on cardiopulmonary fitness in patients with long COVID-19: a randomized controlled trial.

Effects of aerobic training on cardiopulmonary fitness in patients with long COVID-19: a randomized controlled trial.

Publication date: Oct 03, 2024

Long COVID-19 is characterized by systemic deterioration of the entire body, leading to significant physical and mental disorders. Exercise training has the potential to improve persistent symptoms and cardiopulmonary functions. This was a single-center, randomized, controlled trial. Twenty-four patients aged 18 to 75 years who had a history of SARS-CoV-2 infection and long COVID symptoms. Patients were randomly allocated in a 1:1 ratio to receive either a 4-week exercise training program or an attention control group. The training group participated in 12 supervised aerobic sessions on a cycling ergometer over 4 weeks. The outcomes were to assess the impact of a 4-week aerobic exercise on the persistent symptoms and cardiopulmonary fitness, the surrogate endpoints of COVID-19 recovery and cardiopulmonary health. After the 4-week intervention, significant reductions were observed in the total number of symptoms in the training group. Specifically, 67. 8% of patients in the training group exhibited reduced or completely resolved symptoms, in comparison to 16. 7% in the control group (P = 0. 013). After adjusting for gender, significant improvements in the training group were observed for exercise time (P = 0. 028), maximum load (P = 0. 01), and peak VO (P = 0. 001), as well as O pulse (P = 0. 042) and maximum heart rate (P = 0. 007). The score of Short Form-12, depression, anxiety, perceived stress, and insomnia did not show significant changes between groups (P > 0. 05). A supervised aerobic training program has the potential to alleviate persistent symptoms and improve exercise tolerance in patients with long COVID-19. Further research is necessary to confirm these effects in a large population. This intervention could be easily implemented in non-hospital settings, potentially benefiting a broader range of individuals. ClinicalTrials. gov NCT05961462. Registered on July 25, 2023.

Open Access PDF

Concepts Keywords
Cardiopulmonary Adolescent
Cycling Adult
July Aged
Nct05961462 Cardiopulmonary function
Training Cardiorespiratory Fitness
COVID-19
Exercise
Exercise Therapy
Exercise training
Female
Humans
Long COVID-19
Male
Middle Aged
Persistent symptoms
Post-Acute COVID-19 Syndrome
SARS-CoV-2
Time Factors
Treatment Outcome
Young Adult

Semantics

Type Source Name
disease MESH long COVID
disease MESH mental disorders
disease IDO history
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO intervention
disease MESH depression
disease MESH anxiety
disease MESH insomnia
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH emergency
disease MESH chest pain
disease MESH infection
disease MESH post traumatic stress disorder
pathway REACTOME Metabolism
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Ranitidine
disease MESH cognitive impairment
disease MESH memory loss
disease MESH dyspnea
disease MESH anosmia
disease MESH ageusia
disease MESH hair loss
disease MESH exercise induced asthma
disease MESH neuromuscular diseases
disease MESH unstable angina
drug DRUGBANK Oxygen
disease MESH heart failure
disease MESH arrhythmia
disease MESH hypertension
disease IDO blood
disease MESH lifestyle
disease MESH cardiovascular risk factors
disease MESH Anxiety Disorder
disease IDO symptom
disease MESH Ramp
drug DRUGBANK Carbon dioxide
disease MESH brain fog
disease MESH neuroinflammation
disease MESH Unemployment
disease MESH Education level
disease MESH Comorbidity
disease MESH Hyperlipidemia
drug DRUGBANK Trestolone
disease MESH tic
disease MESH chronic fatigue syndrome
disease MESH cardiovascular disease
pathway KEGG Viral myocarditis
disease MESH functional status
disease MESH stroke
drug DRUGBANK Ademetionine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH syndrome
disease MESH insulin sensitivity
disease MESH metabolic syndrome
disease IDO susceptibility
disease MESH myopathies
pathway REACTOME Translation
disease MESH Alzheimer disease
pathway KEGG Alzheimer disease
disease MESH sequelae
disease MESH Physical inactivity
disease MESH respiratory failure
disease MESH acute coronary syndrome
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Acetohydroxamic acid
disease MESH myocardial infarction

Original Article

(Visited 2 times, 1 visits today)